Wang Hui, Remke Marianne, Horn Thomas, Schwamborn Kristina, Chen Yiyao, Steiger Katja, Weichert Wilko, Wester Hans-Jürgen, Schottelius Margret, Weber Wolfgang A, Eiber Matthias
Department of Nuclear Medicine, West China Hospital, Sichuan University, Guo Xue Xiang 37, Chengdu, 610040, Sichuan, China.
Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Str. 22, 81675, Munich, Germany.
EJNMMI Res. 2023 Nov 16;13(1):99. doi: 10.1186/s13550-023-01044-8.
Targeting prostate-specific membrane antigen (PSMA) has been highly successful for imaging and treatment of prostate cancer. However, heterogeneity in immunohistochemistry indicates limitations in the effect of imaging and radionuclide therapy of multifocal disease. Tc-PSMA-I&S is a γ-emitting probe, which can be used for intraoperative lesion detection and postsurgical autoradiography (ARG). We aimed to study its intraprostatic distribution and compared it with (immuno)-histopathology.
Seventeen patients who underwent RGS between 11/2018 and 01/2020 with a total of 4660 grids were included in the preliminary analysis. Marked intratumor and intra-patient heterogeneity of PSMA expression was detected, and PSMA negative foci were observed in all samples (100%). Heterogeneous intra-patient PSMA-ligand uptake was observed, and no significant correlation was present between the degree of heterogeneity of PSMA expression and PSMA-ligand uptake. Higher PSMA-ligand uptake was observed in GS ≥ 8 than GS < 8 (p < 0.001). The appearance of Gleason Pattern (GP) 4 was strongly associated with higher uptake (coefficient: 0.43, p < 0.001), while GP 5 also affected the uptake (coefficient: 0.07, p < 0.001).
PSMA expression and PSMA-ligand uptake show marked heterogeneity. Prostate carcinoma with GP 4 showed significantly higher uptake compared with non-neoplastic prostate tissue. Our analyses extend the scope of applications of radiolabeled PSMA-ligands to ARG for identifying high-grade disease and using its signal as a noninvasive biomarker in prostate cancer.
靶向前列腺特异性膜抗原(PSMA)在前列腺癌的成像和治疗方面取得了巨大成功。然而,免疫组织化学中的异质性表明多灶性疾病在成像和放射性核素治疗效果方面存在局限性。锝标记的PSMA-I&S是一种发射γ射线的探针,可用于术中病变检测和术后放射自显影(ARG)。我们旨在研究其在前列腺内的分布,并将其与(免疫)组织病理学进行比较。
对2018年11月至2020年1月期间接受机器人辅助根治性前列腺切除术(RGS)的17例患者(共4660个网格)进行了初步分析。检测到PSMA表达存在明显的肿瘤内和患者内异质性,并且在所有样本(100%)中均观察到PSMA阴性灶。观察到患者内PSMA配体摄取存在异质性,并且PSMA表达的异质性程度与PSMA配体摄取之间不存在显著相关性。在Gleason评分(GS)≥8的患者中观察到的PSMA配体摄取高于GS<8的患者(p<0.001)。Gleason模式(GP)4的出现与较高的摄取密切相关(系数:0.43,p<0.001),而GP 5也影响摄取(系数:0.07,p<0.001)。
PSMA表达和PSMA配体摄取表现出明显的异质性。与非肿瘤性前列腺组织相比,具有GP 4的前列腺癌显示出明显更高的摄取。我们的分析将放射性标记的PSMA配体的应用范围扩展到ARG,用于识别高级别疾病并将其信号用作前列腺癌的非侵入性生物标志物。